How “Regulatory Sandboxes” Offer Hope For New Technologies That Don’t Fit The Regulatory Mold

Globally, a new regulatory approach is being adopted increasingly frequently to understand and manage the growing number of cutting-edge medical technologies that sit uncomfortably within current regional or local regulatory structures.

Child playing with his truck toy on a sunny summer day sandy background.
A Safe Space For Regulators, Industry And Other Stakeholders To Play With Innovative Device Concepts • Source: Shutterstock

The pace of medtech innovation seems inexorable. So much advanced technology is becoming available, including through digital health and artificial intelligence, which is revolutionizing the way medical devices and IVDs are being designed and used. Medtech products that do not sit well within the confines of current regulatory environments are becoming increasingly commonplace.

With the promise of exciting new devices and services for patients, and lower costs for health services, there are a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography

Liquid Biopsy Startup Mursla Bio Launches AI Precision Medicine Platform

 

The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.

Prix Galien Spotlights Mental Health ‘Renaissance’ But Systemic Hurdles Persist

 

Experts at the Prix Galien UK Forum discussed the future of mental health innovation, emphasizing the important roles of digital solutions, diagnostic biomarkers and community involvement.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By 

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.